The gene editing technology developer is the latest spinout emerging out of the lab of David Liu at Broad Institute.
Prime Medicine, a US-based gene-editing technology developer spun out of Broad Institute, has emerged from stealth with $315m of series A and B funding.
The company raised $115m in a series A round backed by GV, a corporate venturing subsidiary of internet and technology group Alphabet, together with Arch Venture Partners, Newpath Partners and Fidelity’s F-Prime Capital unit.
Prime Medicine concurrently unveiled a $200m series B round featuring all the series A investors in addition to Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, PSP Investments, Redmile Group, Samsara BioCapital, funds and accounts advised by T Rowe Price, and unspecified life science investment funds.
Founded in 2019, Prime Medicine has built a technology platform designed to modify genetic sequences within the genome to correct disease-causing genetic mutations.
The startup is using gene-editing technology to advance a number of drug discovery programmes targeted at areas such as…
